Raymond James lifts FactSet rating on cheaper valuation, signs of revenue rebound

Raymond James upgraded FactSet Research Systems to Market Perform from Underperform, asserting that the stock's forward price-to-earnings multiple of approximately 24x, near a five-year low and in line with the S&P 500, now reflects competitive and budgeting pressures. The upgrade is underpinned by FactSet's largely recurring revenue, strong client retention, and an early pickup in organic Annual Subscription Value (ASV) growth, which rose 40 basis points sequentially to 4.5% in Q3, breaking an eight-quarter deceleration. While the firm noted ongoing spending constraints from investment management clients and competition from Refinitiv will cap near-term upside, and past capex for AI tools has impacted operating margins (expected to abate by FY26), Raymond James now views the risk and reward as relatively balanced following the stock's de-rating.

Analysis

Raymond James has upgraded FactSet Research Systems (FDS) to Market Perform from Underperform, primarily driven by a valuation de-rating that now appears to have priced in significant headwinds. The company's forward price-to-earnings multiple has contracted to approximately 24x, a level near its five-year low and now in line with the broader S&P 500, erasing its historical premium. This valuation shift is viewed as creating a balanced risk-reward profile. Supporting this view is a crucial inflection in a key performance metric: organic Annual Subscription Value (ASV) growth rose 40 basis points sequentially to 4.5% in the third quarter, breaking an eight-quarter trend of deceleration. However, significant near-term challenges persist, with Raymond James highlighting that spending constraints among investment management clients and intensified competition from LSEG's Refinitiv will likely cap upside in revenue and ASV growth. Furthermore, past capital expenditures, including investments in generative AI, have compressed operating margins by an estimated two percentage points this fiscal year, a drag that is not expected to substantially ease until fiscal year 2026.

Key Decisions for Investors

• Given FactSet's valuation has reset to market levels and key growth metrics show signs of stabilization, investors may consider the stock to be fairly valued, suggesting the thesis for an underperform rating or short position has weakened.
• Potential investors should closely monitor the trajectory of Annual Subscription Value (ASV) growth in subsequent quarters, as sustained momentum beyond the recent 4.5% increase is critical to confirming a durable recovery and justifying multiple expansion.
• Be mindful that near-term upside is likely constrained by persistent client budget pressures and fierce competition from LSEG, making this a potential hold for current investors rather than a compelling new buy for those seeking rapid appreciation.
• For those with a longer investment horizon, the anticipated easing of margin pressure in fiscal 2026 as capex normalizes could present a future catalyst, suggesting the current price may be a reasonable entry point for patient capital.